ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2609

Anti-angiogenic VEGF-A165b Is Associated with Systemic Sclerosis Peripheral Vasculopathy

Victoria Flower1, Shaney Barratt 2, Darren Hart 3, Amanda Mackenzie 4, Jacqueline Shipley 3, Stephen Ward 4 and John Pauling 1, 1Department of Rheumatology, Royal National Hospital of Rheumatic Diseases, Royal United Hospitals NHS Foundation Trusts, Bath, England, United Kingdom, 2North Bristol NHS Trust, Bristol, England, United Kingdom, 3Department of Clinical Measurement, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Trust, Bath, England, United Kingdom, 4Centre for Therapeutic Innovation & Department of Pharmacy and Pharmacology, University of Bath, Bath, England, United Kingdom

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Systemic sclerosis, ultrasound and plasma, VEGF

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: Systemic Sclerosis & Related Disorders – Clinical Poster III

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: The anti-angiogenic isoform of Vascular Endothelial Growth Factor-A (VEGF-A165b) has been implicated in Systemic sclerosis (SSc) vasculopathy. High frequency ultrasound (HFUS) is a novel approach to assessing digital perfusion. We report on the relationship between plasma VEGF-A165b and peripheral microvascular perfusion using HFUS in SSc.

Methods: Fifty-one patients fulfilling 2013 ACR/EULAR criteria for SSc and fifteen healthy controls (HC) underwent HFUS Doppler assessment of microvascular flow at the distal middle finger, from which a Vascularity Index was calculated. Plasma VEGF-A165b levels were assessed using ELISA. Ongoing administration of vasodilator and disease modifying therapies were permitted.

Results: Plasma VEGF-A165b was detectable in 16/51 (31%) of SSc with a peak level of >4000pg/mL (Figure 1). In contrast, only 3/15 (20%) healthy controls had plasma VEGF-A165b greater than the lower limit of detection by ELISA, with a maximum plasma level of 46pg/mL. Median levels were not significantly different between groups. When VEGF-A165b was detectable, it was associated with significantly reduced Vascularity Index in SSc (Figure 2). In contrast, HC showed no difference in the Vascularity Index irrespective of VEGF-A165b. Additionally, the Vascularity Index correlated with VEGF-A165b in SSc (Spearman’s ρ = -0.289, p=0.039) but not HC. The Vascularity Index was reduced in SSc even in those with undetectable VEGF-A165b compared to HC (both with detectable (p=0.047) and undetectable (non-significant) VEGF-A165b).

Conclusion: Increased levels of VEGF-A165b are associated with reduced digital vascularity in SSc. Low levels of VEGF-A165b are sometimes detected in HC but are not associated with reduced digital perfusion. Peripheral vascular compromise in SSc is evident even in the absence of detectable VEGF-A165b. Further longitudinal studies are needed to investigate the role of VEGF-A165b in determining microvascular flow and the impact of disease duration and intervention on VEGF-A165b and digital perfusion over time.


Disclosure: V. Flower, None; S. Barratt, None; D. Hart, None; A. Mackenzie, None; J. Shipley, None; S. Ward, None; J. Pauling, Boehringer Ingelheim, 5, Chugai Roche, 9.

To cite this abstract in AMA style:

Flower V, Barratt S, Hart D, Mackenzie A, Shipley J, Ward S, Pauling J. Anti-angiogenic VEGF-A165b Is Associated with Systemic Sclerosis Peripheral Vasculopathy [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/anti-angiogenic-vegf-a165b-is-associated-with-systemic-sclerosis-peripheral-vasculopathy/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-angiogenic-vegf-a165b-is-associated-with-systemic-sclerosis-peripheral-vasculopathy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology